Spectrum and Excess Risk of Gastrointestinal Tumors in Li-Fraumeni Syndrome

Clin Gastroenterol Hepatol. 2024 Mar;22(3):662-665.e1. doi: 10.1016/j.cgh.2023.08.028. Epub 2023 Sep 14.

Abstract

Li-Fraumeni syndrome (LFS), linked to heterozygous germline pathogenic/likely pathogenic variants in TP53, confers exceptionally high cancer risk, including core cancers (sarcoma, breast, adrenocortical, and brain cancer) among many other cancer types.1 Colorectal cancer (CRC) is most common after the core and hematologic cancers, accounting for ∼2.8% of diagnoses. Stomach and esophageal cancers constitute another 1.3% (TP53 Database; R20, July 2019: https://tp53.isb-cgc.org).2.

MeSH terms

  • Gastrointestinal Neoplasms* / epidemiology
  • Gastrointestinal Neoplasms* / etiology
  • Genetic Predisposition to Disease
  • Germ-Line Mutation
  • Humans
  • Li-Fraumeni Syndrome* / complications
  • Li-Fraumeni Syndrome* / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Tumor Suppressor Protein p53